A Long-term Observational Study in Participants Who Have Received PBGENE-HBV
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Precision BioSciences, Inc.
- Study ID
- NCT07254208
- Status
- Enrolling By Invitation
Conditions
- Chronic HBV Infection
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- PBGENE-HBV — BIOLOGICALPBGENE-HBV is the investigational product administered in the parent study. This LTFU study is non-interventional; no investigational product given.
Study Details
Participants who received at least one dose of PBGENE-HBV will be enrolled in this LTFU study.
Key Dates
- Start date
- Dec 25, 2025
- Status verified
- Apr 2026
- Primary completion
- Jan 31, 2040
- Completion
- Jun 30, 2040
Study Design
- Enrollment
- 45 participants (estimated)
Primary Outcome Measure
Safety to assess frequency, severity, and outcome of delayed adverse events [ Time Frame: 15 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Massachusetts General Hospital/Harvard University | Boston | Massachusetts | 02114 | - |
Find similar trials in Boston, MA
By research site